Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Cocktail & Poster Display session

2P - SOT102, a novel CLDN18.2-targeting antibody-drug conjugate for gastric and pancreatic cancer with a wide range of the tumor target expression


06 Mar 2023


Cocktail & Poster Display session


Radek Spisek


Annals of Oncology (2023) 8 (1suppl_2): 100899-100899. 10.1016/esmoop/esmoop100899


R. Spisek

Author affiliations

  • R&d, SotioBiotech, 170 00 - Prague/CZ


This content is available to ESMO members and event participants.

Abstract 2P


Claudin (CLDN) 18.2, a member of a large family of transmembrane proteins with distinct functions, has been shown to have high prevalence, predominantly in gastric and pancreatic cancer. Ectopic expression of CLDN18.2 was also described in certain proportion of ovarian cancer, NSCLC, hepatocellular cancer and colorectal cancer. Healthy tissue expression is restricted to the stomach epithelium.


SOT102 represents a novel CLDN18.2 targeting antibody-drug conjugate based on a proprietary monoclonal antibody conjugated to a derivative of PNU-159682 via site-specific sortase mediated conjugation. The CLDN18.2 protein sequence is highly conserved across species with a 100% identity in the targeted extracellular loop among rodents, cynomolgus monkeys and humans.


SOT102 showed an excellent specificity for CLDN18.2 and strong binding to the target followed by an efficient tumor cell killing. Preferential binding to selected patient-derived tumor tissues was observed ex vivo when compared to the healthy stomach tissues from mice and cynomolgus monkeys. Single-agent therapeutic activity of SOT102 was demonstrated in numerous patient-derived xenograft models (gastric, pancreatic, liver, colon and lung adenocarcinomas). Complete responses were observed in all CLDN18.2 positive models, irrespective of the intensity of staining. models, independent of CLDN18.2 expression levels, ranging from low (IHC1+) to high (IHC3+), with minimum effective doses between 0.2 mg/kg and 0.6 mg/kg. An acceptable tolerability profile was observed in the toxicity studies at 10 mg/kg (mouse), 6 mg/kg (rat) and 1 mg/kg (cynomolgus monkey), providing a therapeutic index of approximately 10. SOT102 demonstrated favorable pharmacokinetic properties with the half-live in the range of 8 days and 13 days in cynomolgus monkeys and rats, respectively. SOT102 remains stable without any significant loss of the payload both in vitro and in animal models.


SOT102 represents a novel potent ADC with the potential to treat Claudin 18.2 expressing tumors irrespective of the intensity of expression. The first in human dose escalation trial has been initiated in patients with gastric and pancreatic cancer.

Clinical trial identification


Editorial acknowledgement

Legal entity responsible for the study

Sotio Biotech.


Sotio Biotech.


R. Spisek: Financial Interests, Personal, Stocks/Shares: Sotio Biotech.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.